- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
ALK Antibody / EML4-ALK Fusion Protein Antibody [clone RM361] (R20381)
Email: info@nsjbio.com
| Catalog No | Formulation | Size | Price (USD) | ||
|---|---|---|---|---|---|
|
R20381-0.1ML | Antibody in PBS with 50% glycerol, 1% BSA and 0.09% sodium azide | 100 ul | 439 |
|
| Availability | 1-3 business days |
| Species Reactivity | Human |
| Format | Purified |
| Host | Rabbit |
| Clonality | Recombinant Rabbit Monoclonal |
| Isotype | Rabbit IgG |
| Clone Name | RM361 |
| Purity | Protein A purified from animal origin-free supernatant |
| UniProt | Q9UM73 |
| Localization | Cytoplasmic, nuclear |
| Applications | Western Blot : 1:1000-1:2000 |
| Limitations | This ALK Antibody / EML4-ALK Fusion Protein Antibody is available for research use only. |
|
Review this product on BioCompare and get a $20 Amazon gift card
|
Related Products
|
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase belonging to the insulin receptor superfamily that functions in neuronal development, intracellular signaling, and cellular differentiation pathways. ALK Antibody / EML4-ALK Fusion Protein Antibody recognizes total ALK protein including oncogenic ALK fusion proteins associated with constitutive kinase activation and tumor progression in multiple malignancies.
ALK antibody, also referred to as EML4-ALK antibody and Anaplastic lymphoma kinase antibody in the literature, is widely used in molecular oncology, precision medicine, and targeted therapy research applications. Recombinant rabbit monoclonal clone RM361 was generated against a peptide corresponding to the C-terminus of human ALK, supporting detection of both native ALK and clinically relevant ALK fusion proteins.
ALK rearrangements are among the most significant oncogenic driver events identified in non-small cell lung carcinoma (NSCLC), particularly lung adenocarcinoma. The most extensively characterized ALK rearrangement involves fusion between echinoderm microtubule-associated protein-like 4 (EML4) and ALK, generating constitutively active EML4-ALK fusion kinases capable of driving persistent downstream signaling independent of normal receptor regulation. These fusion proteins activate proliferative and survival-associated pathways including MAPK, PI3K-AKT, JAK-STAT, and PLCgamma signaling cascades.
EML4-ALK fusion-positive tumors represent clinically actionable molecular subsets associated with sensitivity to ALK-targeted kinase inhibitors. Consequently, ALK fusion detection has become highly important in precision oncology and translational cancer research. Multiple EML4-ALK fusion variants have been identified, each characterized by distinct breakpoint structures and biologic properties influencing oncogenic signaling and therapeutic response patterns.
Western blot analysis using clone RM361 demonstrates detection of EML4-ALK variant 3 in the NSCLC cell line H2228, supporting recognition of clinically relevant ALK fusion-associated protein species. The observed band near approximately 80 kDa is consistent with expression of the EML4-ALK fusion protein rather than full-length native ALK receptor, reflecting the altered molecular architecture generated by chromosomal rearrangement-associated fusion events.
In addition to NSCLC, ALK fusion-associated oncogenic signaling has been implicated in anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, neuroblastoma, and additional malignancies. Persistent kinase activation resulting from ALK rearrangement promotes malignant transformation, survival signaling, migratory behavior, and therapy-responsive oncogenic dependency states.
Because ALK fusion proteins are central drivers of tumor-associated kinase signaling and molecularly targeted therapeutic strategies, antibodies capable of detecting EML4-ALK-associated protein expression remain valuable tools in translational oncology and biomarker-focused research applications. Clone RM361 supports investigation of fusion-associated kinase biology and oncogenic ALK pathway activation within molecularly defined cancer systems.
Together, the available western blot data support the use of ALK antibody clone RM361 for investigating EML4-ALK fusion-associated oncogenic signaling, receptor tyrosine kinase activation, and precision oncology-associated molecular pathways.
For additional ALK and oncogenic kinase research antibodies targeting fusion protein signaling, lung cancer biomarkers, and lymphoma-associated receptor tyrosine kinase pathways, explore the broader ALK Antibody page featuring recombinant rabbit monoclonal clone ALK1/6698R.
The stated application concentrations are suggested starting points. Titration of the ALK Antibody / EML4-ALK Fusion Protein Antibody may be required due to differences in protocols and secondary/substrate sensitivity.
A peptide corresponding to the C-terminus of human ALK (Anaplastic lymphoma kinase) was used as the immunogen for the recombinant ALK antibody.
Store the recombinant ALK antibody at -20oC.
ALK antibody, EML4-ALK antibody, Anaplastic lymphoma kinase antibody, ALK fusion protein antibody, EML4-ALK fusion protein antibody
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.
Powered by Bioz
